title: Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy.
abstract: OBJECTIVE
  To conduct prospective electroglottographic analyses of voice outcomes after radical chemoradiotherapy for locally advanced laryngopharyngeal cancers and to compare them with patients who have undergone total laryngectomy (TL).
  
  
  METHODS
  Twenty-one patients (19 male, 2 female, median age [range] 65 [50-85] years) with Stage III/IV laryngopharyngeal cancer received induction chemotherapy followed by radical chemoradiotherapy. Electroglottography, using the sustained vowel /i/ and connected speech, was performed before treatment and 1, 6, and 12 months after treatment. In addition, single voice recordings were taken from 21 patients (16 male, 5 female, aged 65 [50-84] years) who had undergone TL and surgical voice restoration and from 21 normal controls (18 male, 3 female, aged 65 [33-80] years).
  
  
  RESULTS
  Before treatment the vocal measures for the chemoradiotherapy patients were significantly different from normal controls in jitter (p = 0.02), maximum phonation time (MPT) (p = 0.001), and words per minute (WPM) (p = 0.01). At 12 months after treatment MPT and WPM had normalized, but jitter and normalized noise energy were significantly worse than in normal controls. Comparison of voice outcomes at 12 months for chemoradiotherapy patients revealed superiority over the TL group in all parameters except MPT (18.2 s vs. 10.4 s, p = 0.06). Analysis of the recovery of voice up to 12 months after treatment revealed progressive improvement in most electroglottographic measures.
  
  
  CONCLUSIONS
  This prospective study demonstrates significantly better outcome for patients treated with chemoradiotherapy as compared with TL. Progressive normalization of many voice parameters occurs over the 12 months following chemoradiotherapy.
authors: Head and Neck Unit, Royal Marsden Hospital, London, UK.
authors: Rehan
authors: R
authors: Kazi
authors: Ramachandran
authors: R
authors: Venkitaraman
authors: Catherine
authors: C
authors: Johnson
authors: Vyas
authors: V
authors: Prasad
authors: Peter
authors: P
authors: Clarke
authors: Peter
authors: P
authors: Rhys-Evans
authors: Christopher M
authors: CM
authors: Nutting
authors: Kevin J
authors: KJ
authors: Harrington
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D017097:Electric Impedance; D005260:Female; D005931:Glottis / Q000503:physiopathology; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D007825:Laryngectomy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013065:Speech Intelligibility / Q000187:drug effects / Q000528:radiation effects; D018709:Statistics, Nonparametric; D013997:Time Factors; D014832:Voice Disorders / Q000517:prevention & control; D014833:Voice Quality / Q000502:physiology*
chemical_list: D002945:Cisplatin